Table 4.
Primary study endpoint, by study drug randomization.
| Primary endpoint | Colchicine (n = 24) | Placebo (n = 26) | p value∗ |
|---|---|---|---|
| Combined CMVD: (CFR <2.0 or RRR <2.0 or IMR >32) | 10 (42) | 16 (62) | 0.16§ |
| RRR <2.0 or IMR >32 | 8 (33) | 14 (54) | 0.14§ |
| CFR or RRR <2.0 | 5 (21) | 12 (46) | 0.06§ |
| RRR <2.0 | 3 (13) | 9 (35) | 0.10|| |
| CFR <2.0 | 5 (21) | 12 (46) | 0.06§ |
| IMR >32 | 6 (25) | 8 (31) | 0.65§ |
Values are n (%), ∗denotes comparison between colchicine vs placebo group, § denotes Chi-squared test, and || denotes Fisher's exact test.